180 Life Sciences, a clinical-stage biotechnology company, is dedicated to producing solutions designed to battle inflammation when the body’s natural processes go awry. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, designed to block the activity of TNF, a substance in the body that can cause inflammation and lead to … Continue reading “QualityStocksNewsBreaks – 180 Life Sciences Corp. Advancing Lead Program, Plans Additional Clinical Trials”
Anti-inflammatory therapeutics market to generate revenues of $191.42 billion through 2027 Novel drug therapy for Fibrosis and Anti-TNF trials being conducted by Professor Sir Marc Feldmann, who already developed one of the most commonly used anti-TNF medications, Remicade The number of conditions with chronic inflammation is expected to increase persistently over the next 30 years … Continue reading “180 Life Sciences Corp. Leading Research into Novel Drug Therapies Expected to Produce First Results of Phase 2b/3 Trial in 2021”
KBL Merger Corp. IV is set to finalize the acquisition of 180 Life Sciences Corp. during Q4 2020 180 Life Sciences Corp. has several ongoing programs at different stages of development, with the leading candidate in Phase 2b/3, helping mitigate the risks involved with its drug development The merger with 180 Life Sciences will enable … Continue reading “KBL Merger Corp. IV (NASDAQ: KBLM) Fulfilling IPO Goal Through Merger With 180 Life Sciences Corp.”
180 Life Sciences is a clinical-stage biotechnology company that is developing therapies to combat inflammation in patients with chronic inflammation-related illnesses The company is being acquired by special purpose acquisition corporation KBL Merger Corp. IV (NASDAQ: KBLM) and will be listed on the Nasdaq Capital Market under ticker symbol ATNF when the deal closes later … Continue reading “180 Life Sciences Corp. Pursuing Novel Solutions to Inflammatory Illnesses as Merger Nears Completion”
180 Life Sciences, a clinical-stage biotechnology company, is focused on the development of novel drugs that fulfill unmet needs for a variety of conditions including fibrosis, pain and inflammatory diseases. 180 Life Sciences will soon form a combined company with KBL Merger Corp. IV (NASDAQ: KBLM), a special purpose acquisition corporation (“SPAC”), with the new … Continue reading “QualityStocksNewsBreaks – Why 180 Life Sciences Corp. Is ‘One to Watch’”
180 Life Sciences boasts a world-class team responsible for developing new classes of drugs targeting multiple disease states while creating significant shareholder value The company has a large and expanding patent portfolio The risks associated with the company’s drug development efforts are mitigated through the concurrent advancement of multiple programs in different stages of development … Continue reading “180 Life Sciences Corp. is “One to Watch””
KBL Merger Corp. IV (NASDAQ: KBLM), a special purpose acquisition corporation (SPAC), announced that, in connection with its previously detailed merger agreement with 180 Life Sciences, it consummated a bridge financing on June 29, 2020, and submitted its latest S4 filing with the SEC on August 28, 2020. It expects to close the business combination … Continue reading “180 Life Sciences Corp.”
Federal four-year grant awarded to Ohio State University to fund research program with PBIO Goal is development of manufacturing process to keep foods fresh without costly refrigerated transport/storage and safe without chemical additives PBIO’s Ultra-Shear Technology (“UST”) allows food manufacturers to manufacture healthier beverages and other foods that retain flavor and preserve product’s wholesome ingredients, … Continue reading “Pressure BioSciences, Inc. (PBIO) Patented Ultra-Shear Technology Focus of New Government-Funded Food Safety Program”
Biologics offer novel ways of treating degenerative diseases like Alzheimer’s Biologics are one of the fastest-growing drug categories PreEMT™ technology improves quality, reduces cost of biologic manufacture When we think of drugs, an image of potions in round-bottom flasks conjured up in labs comes to mind, or perhaps pills of one sort or another ingested … Continue reading “Pressure BioSciences Inc.’s (PBIO) Recently Acquired PreEMT™ Platform Enhances Development of Biotherapeutic Protein Drugs”
Grey Cloak Tech Inc. (GRCK), through its growing portfolio of wholly owned subsidiaries, is engaged in the proprietary research and development of natural plant-based formulations, sales, and distribution of cardiovascular and neuro products. The company’s focus is to advance its market positions in the broader health industry through the unique assets and operations of its … Continue reading “Grey Cloak Tech Inc. (GRCK)”
